Restoration of Innate and Adaptive Immune Responses by HCV Viral Inhibition with an Induction Approach Using Natural Interferon-Beta in Chronic Hepatitis C

Table 1

Characteristics of chronic hepatitis C with high viral load, serotype-1 (genotype 1b), and wild or intermediate type in ISDR before, during, and after RBV plus PEG-IFN-alpha 2b using an “induction” therapy with cyclic and periodic interferon treatment (CPIT); novel combination treatment (NCT).

Patient NO.							ALT (lU/mL)
	Age/gender	Body weight (kg)	BMI (kg/m^2)	Liver histology (Stage/Grade)	baseline	24 weeks (end of NCT)	72 weeks (end of NCT)	96 weeks (24 weeks after end of NCT)	Outcome of treatment
Early virologic responders
1	61/F	46.1	20.4	1/2	197	37	15	13	SBR
2	47/M	67.0	21.1	1/1	37	28	22	22	SBR
3	66/M	78.0	24.5	3/2	57	29	29	17	SBR
4	49/M	60.0	19.8	1/2	50	32	12	11	SBR
5	61/F	48.5	20.9	1/2	38	9	14	10	SBR
Late virologic responders
6	39/F	73.0	27.1	1/2	48	331	264	161	NBR
7	56/F	55.0	20.6	−/−	33	19	13	49	TBR
Mean ± SD.	53.3±8.5	61.1±12.1	22.1±2.7	1–3/1-2	65.7±58.5	69.3±115.8	52.7±93.3	39.0±59.9

IFN: interferon, BMI: body mass index, ISDR: IFN sensitivity determining region, F: female, M: male, SBR: sustained biochemical response, NBR: no biochemical response, and TBR: transient biochemical response.